The Role of Bevacizumab in the Treatment of Non-Small Cell Lung Cancer: Current Indications and Future Developments

Abstract

After completing this course, the reader will be able to:1. Describe the main clinical trials of bevacizumab combined with chemotherapy in the treatment of advanced NSCLC.2. Describe the main clinical trials of bevacizumab combined with other targeted therapies in the treatment of advanced NSCLC.3. Describe some ongoing trials of bevacizumab in the treatment of NSCLC and try to define future developments of bevacizumab in this clinical setting.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACT

Carcinostatic effect of allergen removed Rhus Verniciflua stokes based Traditional Korean Medicine on a patient with lung adenocarcinoma; single case report

“…These days, cytostatic agents are being considered as novel medication in the treatment of cancer with prolonged survival period and lower toxicity compared with the cytotoxic chemotherapy agent previously used. One of the approaches of targeted agent is the inhibition of angiogenesis (Gridelli et al, 2007). Because of the presumed cytostatic mechanism of action of these agents, however, the efficacy is most appropriately assessed through survival end points rather than the objective-response end points that have traditionally been used with cytotoxic agents (Ellis, 2006).…”

“…One of the approaches of targeted agent is the inhibition of angiogenesis, and these targeted agents usually induced cytostatic effects contrary to the most chemotherapy agents which have cytotoxic Jong-Soo Jeong et al properties to the cancer cells (Gridelli et al, 2007).…”

The antitumor activity of an anti‐CD54 antibody in SCID mice xenografted with human breast, prostate, non‐small cell lung, and pancreatic tumor cell lines

“…In the past few years several new targets have been identified for NSC lung cancer, most notably EGFR and VEGF, and it is hoped that they will translate to improved treatment outcomes. [49][50][51] Since CD54 is also up-regulated on a majority of NSC lung tumor cell lines investigated in this and other studies, 21,22 it might represent another important therapeutic target. When administered to SCID/NSC lung tumor mice, UV3 slowed the growth of palpable tumors, both alone and in combination with chemotherapy.…”

Role of VEGF gene polymorphisms in the clinical outcome of non-small cell lung cancer

“…A majority of the NSCLC patients are diagnosed during the advanced stages of the disease; in addition, a large number of those diagnosed during the early stages of the disease display eventual recurrence, metastatic disease, and overall poor prognosis (Gridelli et al, 2007). Platinum-based combination chemotherapy, which inhibits multiple biological pathways and mediates tumor growth, has been identified as an effective therapeutic strategy (Jung et al, 2002).…”